KBC

MICLEDI Microdisplays BV specializes in designing and manufacturing micro light-emitting diode (microLED) display chips tailored for augmented reality (AR) glasses. Based in Leuven, Belgium, the company operates as a fabless developer, focusing on advanced technology that integrates III/V materials processing, 3D integration, and 300mm silicon-based processing. MICLEDI's proprietary application-specific integrated circuit (ASIC) enables the production of compact, monolithic AR displays that deliver high image quality and enhanced power efficiency. By providing microLED display modules on wafers, MICLEDI serves the semiconductor industry, contributing to the advancement of AR technology.

ArtiQ is an innovative spin-off from the University of Leuven, founded in early 2019 by a team with extensive experience in respiratory medicine, medical devices, and artificial intelligence. The company focuses on developing AI-backed software to support medical professionals in diagnosing, treating, and monitoring patients with lung diseases. By automating the interpretation of pulmonary function tests, ArtiQ's technology enhances the accuracy and efficiency of the diagnostic process, facilitating the early detection of disease patterns. This approach not only aids healthcare practitioners in making informed decisions but also aims to improve the overall environment for lung disease diagnostics, ultimately benefiting patients and the healthcare system. ArtiQ aspires to be a trusted partner for medical practitioners in addressing respiratory issues.

Interlease is a Bulgarian leasing company that operates under the umbrella of the Belgian banking and insurance group KBC. It specializes in providing financing and leasing services for a variety of assets, including high-quality equipment, transportation vehicles, and office supplies. By enabling Bulgarian enterprises to acquire necessary resources, Interlease aims to enhance their competitiveness and market positions both locally and internationally. The company also emphasizes customer support after the delivery of assets by utilizing effective internet and mobile technologies, allowing clients to select their preferred suppliers and asset types that best fit their business needs.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

Aristo Music NV develops selection and distribution techniques and technologies for digital music and provides music related services. The company also develops various Internet applications, which include a Web radio that consists of a musical database. It serves catering, retail, business, leisure, and government markets. The company is based in Heverlee, Belgium.

Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics for pets and livestock. It operates a proprietary platform dedicated to creating innovative treatments for significant viral diseases, with five candidates currently in clinical or development stages. The company specializes in addressing viral infections affecting pets, particularly through its work on feline herpes and feline immunodeficiency virus. Okapi Sciences is committed to advancing its pipeline of antiviral drugs while fostering strong relationships with academic institutions to enhance its research capabilities and technological advancements in veterinary medicine.

Movetis NV is a pharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting gastrointestinal (GI) disorders. The company addresses a range of conditions, including severe chronic constipation, ascites, and pediatric reflux, as well as severe GI motility disorders like refractory gastro-oesophageal reflux disease. Its lead product, Resolor, is specifically designed for the symptomatic treatment of chronic constipation in women, with ongoing research for its efficacy in males and children, as well as in cases of opioid-induced constipation and post-operative ileus. Movetis is also developing M0002, currently in Phase II trials for treating ascites, and M0003, which is set to enter Phase II development for symptomatic relief of heartburn and regurgitation in patients unresponsive to proton pump inhibitors. Additionally, the company has two prioritized compounds from its preclinical portfolio and maintains partnerships with universities in Ghent, Leuven, and Rotterdam. Founded in 2006, Movetis is based in Turnhout, Belgium.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.